CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
双特异性抗体与 T 细胞导向治疗在非霍奇金淋巴瘤中的现状
英文原题：The Current State of Bispecific Antibodies and T-Cell Directed Therapy in NHL.
查看英文原题
The Current State of Bispecific Antibodies and T-Cell Directed Therapy in NHL.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
复发/难治性非霍奇金淋巴瘤（r/r NHL）是一种侵袭性疾病，化学免疫治疗和自体干细胞移植的总体缓解率较低，弥漫性大B细胞淋巴瘤患者尤为如此。该领域的重要进展来自新型免疫疗法的应用，包括靶向CD19/CD20的CAR-T 细胞和双特异性抗体。这些新疗法持续改变r/r NHL治疗格局，并已扩展至更早治疗线，显示出疗效和患者安全性。本综述详细讨论这些疗法在复发/难治性NHL管理中的作用及未来研究方向。
展开英文摘要原文
Relapsed/refractory non-Hodgkin lymphoma (r/r/NHL) is an aggressive disease with overall poor response rates to chemo-immunotherapy and autologous stem-cell transplant, especially in patients with diffuse large B-cell lymphoma. Major improvements in this disease space have come through the incorporation of novel immune therapies, including CD19/CD20 directed CAR-T cells and bispecific antibodies.
These exciting new therapies continue to change the landscape of treatment for r/r NHL and have been incorporated in earlier lines of therapy with demonstrated efficacy and patient safety. In this review, the role of these treatments in the management of relapsed/refractory NHL is discussed in detail along with future directions of research.
论文信息
- 作者
- Kordic A、Phillips TJ、Weiss J
- 第一作者单位
- City of Hope Comprehensive Cancer Center, Department of Hematology and Hematopoietic Cell Transplantation, Division of Lymphoma, Duarte, CA 91010, USA.United States
- 通讯作者单位
- Rogel Comprehensive Cancer Center, University of Michigan-Ann Arbor, Ann Arbor, MI 48109, USA.United States
- 文献类型
- 综述
- 期刊
- Cancers2025 Mar 31
- 原文标识
- PubMed 40227768 · DOI 10.3390/cancers17071192
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →